NEK2 and breast carcinoma: Indeed, breast cancer stem cells exhibited a marked decrease in miRNA-128 levels, and its overexpression was found to inhibit self-renewal ‘in vitro’ and tumorigenicity ‘in vivo’ by blocking the mitotic NIMA-related kinase 2 (NEK2) [73].